UBS lowered the firm’s price target on Jasper Therapeutics (JSPR) to $33 from $38 and keeps a Buy rating on the shares. Following the Q1 earnings report, all eyes are on the upcoming updates on briquilimab in chronic inducible urticaria and chronic spontaneous urticaria, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Promising Advancements in Jasper Therapeutics’ Briquilimab Programs Highlight Market Potential
- Positive Outlook for Jasper Therapeutics: Promising Clinical Developments and Strategic Updates Support Buy Rating
- Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs
- Jasper Therapeutics reports Q1 EPS ($1.41), consensus ($1.48)
- JSPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?